Everything below concerns receptor targets. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-04. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Placing workers at the heart of changes made, including through workers being placed on company boards The implementation of a "right to disconnect" to prevent AI-enabled remote working from creating an "always-on" culture. Attaching "good work" conditions to public funding for AI research and development. The TUC has also drafted a model Artificial Intelligence (Regulation and Employment Rights) Bill, designed to fill the regulatory gap left by the UK's divergence from EU data protection standards and the absence of a domestic equivalent to the EU AI Act. Prospect, the union representing scientists, engineers, and tech workers, has campaigned for civil servants and technical professionals to have a voice in the rollout of AI. Prospect has highlighted the risks of an "always-on" culture, of the prevalence of workplace surveillance, and the need for workers to have ownership over the data collected about them by their employers.
==== Non-seasonal depression ==== Light therapy has also been suggested in the treatment of non-seasonal depression and other psychiatric mood disturbances, including major depressive disorder, bipolar disorder and postpartum depression. A meta-analysis by the Cochrane Collaboration concluded that "for patients suffering from non-seasonal depression, light therapy offers modest though promising antidepressive efficacy." A 2008 systematic review concluded that "overall, bright light therapy is an excellent candidate for inclusion into the therapeutic inventory available for the treatment of nonseasonal depression today, as adjuvant therapy to antidepressant medication, or eventually as stand-alone treatment for specific subgroups of depressed patients." A 2015 review found that supporting evidence for light therapy was limited due to serious methodological flaws. A 2016 meta-analysis showed that bright light therapy appeared to be efficacious, particularly when administered for 2–5 weeks' duration and as monotherapy.
Tim Hortons reportedly had plans by 2013 to enter the large Indian market, which the company denied. In an effort to expand the company following its 2014 merger with Burger King into Restaurant Brands International, Tim Hortons began expansion in Asia in 2017 citing the increasing demand for coffee in large populations. The first Southeast Asian branch was opened in the Philippines on February 28, 2017, at Uptown Mall in Bonifacio Global City, Taguig. Siera Bearchell, Miss Universe Canada 2016, was present for the ribbon-cutting ceremony. As of December 2023, there are 52 locations operating in the Philippines.
Sources: en.wikipedia.org
Southern blotting A molecular biology method used to detect a specific sequence in DNA samples. The method combines separation of DNA fragments by gel electrophoresis, transfer of the DNA to a synthetic membrane, and subsequent identification of target fragments with radio-labeled or fluorescent hybridization probes. Compare northern blotting, western blotting, and eastern blotting.
Carbon nanotubes are the strongest and stiffest materials yet discovered in terms of tensile strength and elastic modulus. This strength results from the covalent sp2 bonds formed between the individual carbon atoms. In 2000, a multiwalled carbon nanotube was tested to have a tensile strength of 63 GPa (9,100,000 psi). (For illustration, this translates into the ability to endure tension of a weight equivalent to 6,422 kilograms-force (62,980 N; 14,160 lbf) on a cable with cross-section of 1 mm2 (0.0016 sq in)). Further studies, such as one conducted in 2008, revealed that individual CNT shells have strengths of up to ≈100 GPa (15,000,000 psi), which is in agreement with quantum/atomistic models. Because carbon nanotubes have a low density for a solid of 1.3 to 1.4 g/cm3, its specific strength of up to 48,000 kN·m/kg is the best of known materials, compared to high-carbon steel's 154 kN·m/kg. Although the strength of individual CNT shells is extremely high, weak shear interactions between adjacent shells and tubes lead to significant reduction in the effective strength of multiwalled carbon nanotubes and carbon nanotube bundles down to only a few GPa. This limitation has been recently addressed by applying high-energy electron irradiation, which crosslinks inner shells and tubes, and effectively increases the strength of these materials to ≈60 GPa for multiwalled carbon nanotubes and ≈17 GPa for double-walled carbon nanotube bundles. CNTs are not nearly as strong under compression.
=== 22 July === Ukrainian drones set fire to an oil refinery at Tuapse, Krasnodar Krai. Russian officials claimed the fire was put out, with no casualties and no “serious damage”. Russian air defence shot down some 75 drones over night over the Black and Azov Seas and over Belgorod, Voronezh, Smolensk and Rostov Oblasts. Mamuka Mamulashvili, the commander of the pro-Ukrainian militia Georgian National Legion, claimed that the State Security Service of Georgia placed about 300 members of the group on a wanted list. Boeing and Antonov signed a memorandum of understanding to collaborate on drone production and maintenance.
Sources: en.wikipedia.org
Cibaria fere eadem sunt utrique generi praebenda. Nam si tam laxa rura sunt, ut sustineant pecorum greges, omnis sine discrimine hordeacea farina cum sero commode pascit. Sin autem surculo consitus ager sine pascuo est, farreo vel triticeo pane satiandi sunt, admixto tamen liquore coctae fabae, sed tepido, nam fervens rabiem creat. "Provisions of victuals are almost the same for both [types of dog]. If the fields are so large as to sustain herds of animals, barley meal mixed with whey is a convenient food. But if it is an orchard without grain, spelt or wheat bread is fed mixed with the liquid from cooked beans, but warm, for boiling creates rabies." In the Avesta, written from 224 to 651 CE, Ahura Mazda advises:
granulated diatomaceous earth is a raw material simply crushed for convenient packaging milled or micronized diatomaceous earth is especially fine (10 μm to 50 μm) and used for insecticides calcined diatomaceous earth is heat-treated and activated for filters
=== Patent === Toward the end of January 1922, tensions mounted between the four "co-discoverers" of insulin and Collip briefly threatened to separately patent his purification process. John G. FitzGerald, director of the non-commercial public health institution Connaught Laboratories, therefore stepped in as peacemaker. The resulting agreement of 25 January 1922 established two key conditions: 1) that the collaborators would sign a contract agreeing not to take out a patent with a commercial pharmaceutical firm during an initial working period with Connaught; and 2) that no changes in research policy would be allowed unless first discussed among FitzGerald and the four collaborators. It helped contain disagreement and tied the research to Connaught's public mandate.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.